Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

New targets for melanoma treatment
(Monash University) A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

DNA-based nanotechnology stimulates potent antitumor immune responses
(The Wistar Institute) Combining their expertise in protein engineering and synthetic DNA technology, Wistar scientists successfully delivered nanoparticle antitumor vaccines that stimulated robust CD8 T cell immunity and controlled melanoma growth in preclinical models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

UCLA study shows how interferon-gamma guides response to cancer immunotherapy
(University of California - Los Angeles Health Sciences) UCLA researchers shed light on how interferon-gamma (IFN-y) guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -- immune checkpoint blockade. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

New nanosystem from Tel Aviv university enhances treatment for melanoma in animal models
(American Friends of Tel Aviv University) Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro of TAU's Department of Physiology and Pharmacology at the Sackler School of Medicine, have developed an innovative nanotechnological drug delivery system that significantly enhances the effectiveness of treatment for the aggressive skin cancer melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
FRIDAY, Sept. 4, 2020 -- For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2020 Category: Pharmaceuticals Source Type: news

Durable Response: 5 Years After Adjuvant Combo in Melanoma Durable Response: 5 Years After Adjuvant Combo in Melanoma
Double targeted therapy conferred durable long-term relapse-free survival when given in the adjuvant setting in advanced melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 2, 2020 Category: Cancer & Oncology Source Type: news

Effective cancer immunotherapy further linked to regulating a cell 'suicide' gene
(Johns Hopkins Medicine) Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell's natural " suicide " signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer. A summary of the research, conducted with mice and human cells, appeared Aug. 25 in Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2020 Category: Cancer & Oncology Source Type: news

Melanoma Experts Say'No' to Routine Gene Profile Testing Melanoma Experts Say'No' to Routine Gene Profile Testing
False positives, negatives too high.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 26, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Impressive Results' From Stage III Melanoma Studies: ASCO 2020'Impressive Results' From Stage III Melanoma Studies: ASCO 2020
Dr Jeffrey Weber describes three adjuvant and/or neoadjuvant studies in stage III melanoma that piqued his interest at this year's American Society of Clinical Oncology virtual meeting.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 25, 2020 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news

Skin cancer deaths more than DOUBLE in 50 years as British sunseekers jet abroad on cheap holidays
Official figures from Cancer Research UK reveal people are dying from melanoma skin cancer at 2.5 times the rate they were in the 1970s as more Brits jet abroad on cheap holidays. (Source: the Mail online | Health)
Source: the Mail online | Health - August 20, 2020 Category: Consumer Health News Source Type: news

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage
Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I–binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae. Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb–restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti–PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in ...
Source: ScienceNOW - August 20, 2020 Category: Science Authors: Fluckiger, A., Daillere, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., Lemaitre, F., Ferrere, G., Derosa, L., Duong, C. P. M., Messaoudene, M., Gagne, A., Joubert, P., De Sordi, L., Debarbieux, L., Simon Tags: Immunology, Medicine, Diseases r-articles Source Type: news

Better Than Ever: Beyond image, having healthy body takes on new meaning for cancer survivor
After being diagnosed with stage 2D melanoma in December 2017, fintech exec and entrepreneur Nichol Beckstrand made some changes in her life. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2020 Category: Pharmaceuticals Authors: Kim Johnson Source Type: news

Skin cancer symptoms: The major warning signs that could indicate melanoma
SKIN cancer can affect almost anyone and with temperatures progressively intensifying year after year, it's never been more important to be vigilant of one's skin. What are the major warning signs of melanoma? (Source: Daily Express - Health)
Source: Daily Express - Health - August 15, 2020 Category: Consumer Health News Source Type: news

Molecules in urine allow doctors to monitor skin cancer
(De Gruyter) What if you could simply provide a urine sample rather than undergo a painful surgical procedure to find out if your cancer was responding to treatment? It may seem too good to be true, but researchers at Pavol Jozef Š af á rik University in Ko š ice, Slovakia, have identified fluorescent molecules in urine that may allow patients with malignant melanoma to do just that. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma
BRAF and MEK inhibitors might be used in a second-line setting after BRAF pathogenic variant is confirmed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Boston University researcher receives grant to fight melanoma
(Boston University School of Medicine) Deborah Lang, MD, associate professor of dermatology at Boston University School of Medicine (BUSM), has been awarded a two-year, $250,000 grant from the Harry J. Lloyd Charitable Trust to further her basic science research on the molecular and cellular biology of melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 31, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Triple Drug Combo for Melanoma FDA Approves Triple Drug Combo for Melanoma
The triple-therapy combination of atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Media News - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Investor Update - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
South San Francisco, CA -- July 30, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news

Researchers outline need for evaluation of gene expression profiling in melanoma
(Huntsman Cancer Institute) A consensus statement published today in JAMA Dermatology cautions against routine use of currently available GEP tests for patients with cutaneous melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 29, 2020 Category: Cancer & Oncology Source Type: news

Pembrolizumab Use Supported in Advanced Melanoma
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 22, 2020 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Re-treating Melanoma After PD-1 Blockade Shows Good Response Re-treating Melanoma After PD-1 Blockade Shows Good Response
In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? A recent study addresses this important question.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Pembrolizumab Use Supported in Advanced Melanoma
WEDNESDAY, July 22, 2020 -- Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 22, 2020 Category: Pharmaceuticals Source Type: news

New Jersey Oncologist Sentenced to Jail for Misconduct, Theft New Jersey Oncologist Sentenced to Jail for Misconduct, Theft
The former chief of melanoma and soft tissue oncology at the Rutgers Cancer Institute pleaded guilty to charges of computer theft, burglary, and official misconduct.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Melanoma Advances Improved OS in Patients With Brain Mets Melanoma Advances Improved OS in Patients With Brain Mets
Advances in melanoma treatment that emerged between 2007 and 2016 have resulted in a doubling of overall survival for patients with brain metastases.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A helping hand for cancer immunotherapy
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials in oncology, and this research provides a strong rationale for evaluating the drugs in tumors that are not responsive to immune checkpoint therapy. The study was published in Science Translational Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2020 Category: Cancer & Oncology Source Type: news

A Risk Model for Development of Subsequent Primary Melanoma A Risk Model for Development of Subsequent Primary Melanoma
Using demographic, phenotypical, histopathological, sun exposure and genomic risk factors, the authors present a risk prediction model for the development of subsequent primary melanomas.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Vitamin D Tied to Lower Risk for Immunotherapy-Induced Colitis Vitamin D Tied to Lower Risk for Immunotherapy-Induced Colitis
Preliminary results show for the first time that vitamin D intake may be tied to decreased risk for immunotherapy-induced colitis in patients with melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Smoking, Socioeconomic Status, and Cutaneous Melanoma Smoking, Socioeconomic Status, and Cutaneous Melanoma
This study sought to investigate the association of smoking and socioeconomic status on the incidence and survival of melanoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 26, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Study reveals key finding about microbiome of anticancer compound-producing marine invertebrate
(Desert Research Institute) Could the cure for melanoma - the most dangerous type of skin cancer -- be a compound derived from a marine invertebrate that lives at the bottom of the ocean? A group of scientists led by Alison Murray, Ph.D. of the Desert Research Institute (DRI) in Reno think so, and are looking to the microbiome of an Antarctic ascidian called Synoicum adareanum to better understand the possibilities for development of a melanoma-specific drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2020 Category: Cancer & Oncology Source Type: news

Vulvar Melanoma Is Increasing in Older Women Vulvar Melanoma Is Increasing in Older Women
The national incidence of vulvar melanoma is on the rise in women older than 60 years, a study of epidemiologic trends shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
SAN DIEGO, June 23, 2020 -- (Healthcare Sales & Marketing Network) -- Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int'l., (Holdings) Inc., announces that the U.S. ... Biopharmaceuticals, Oncology, FDA Polynoma, Seviprotimut-L, Melanoma, Cancer Vaccine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 23, 2020 Category: Pharmaceuticals Source Type: news

Innovative smartphone-camera adaptation images melanoma and non-melanoma
(SPIE--International Society for Optics and Photonics) An article published in the Journal of Biomedical Optics (JBO), " Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring, " shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2020 Category: International Medicine & Public Health Source Type: news

Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 22, 2020 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news

Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
MONDAY, June 22, 2020 -- For patients with melanoma treated with immune checkpoint inhibitors (ICIs), vitamin D intake is associated with a reduced risk for ICI colitis, according to a study published online June 22 in Cancer. Shilpa Grover, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 22, 2020 Category: Pharmaceuticals Source Type: news

What Are the Five Stages of Melanoma?
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 18, 2020 Category: General Medicine Source Type: news

Wearable patch may provide new treatment option for skin cancer
(Purdue University) Purdue University innovators have created a novel wearable patch to provide an improved treatment experience for people with melanoma. The researchers developed a novel wearable patch with fully miniaturized needles, enabling unobtrusive drug delivery through the skin for the management of skin cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 16, 2020 Category: Cancer & Oncology Source Type: news

Black Melanoma Patients Face Treatment Delays: Study
Title: Black Melanoma Patients Face Treatment Delays: StudyCategory: Health NewsCreated: 6/9/2020 12:00:00 AMLast Editorial Review: 6/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 10, 2020 Category: Cancer & Oncology Source Type: news

Black Melanoma Patients Face Treatment Delays
Black Americans with melanoma, the deadliest form of skin cancer, wait longer for surgery than white patients, a new study finds. (Source: WebMD Health)
Source: WebMD Health - June 9, 2020 Category: Consumer Health News Source Type: news

Black Melanoma Patients Face Treatment Delays: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 9, 2020 Category: Cancer & Oncology Tags: Oncology, Research, News, Source Type: news

Black Melanoma Patients Face Treatment Delays: Study
TUESDAY, June 9, 2020 -- Black Americans with melanoma, the deadliest form of skin cancer, wait longer for surgery than white patients, a new study finds. " We already knew that black patients with melanoma have a worse prognosis and that longer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2020 Category: General Medicine Source Type: news

Racial Differences Seen in Time to Treatment for Melanoma
Time from diagnosis to definitive surgery is twice as long on average for black versus white patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2020 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Surgery, Journal, Source Type: news

Factors Associated With Death From Thin Melanoma Factors Associated With Death From Thin Melanoma
What characteristics of thin melanomas might serve as predictors of high risk of mortality?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news